Evidence map›Paper›PMID 37410717›Full record

ArticlePloS one2023

Quality of life, self-reported outcomes and impact of education among people with moderate and severe hemophilia A: An integrated perspective from a Latin American country.

Liliana Torres, Oscar Peñuela, Maria Del Rosario Forero, Juan Satizabal, Ximena Salazar, Diana Benavides, Raul Gamarra, Marcela Rivera, David Vizcaya, Juan-Sebastian Franco

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. The Epigenetic Landscape of Hemophilia.Current molecular medicine · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liliana TorresMedical Affairs, Bayer S.A., Bogotá, Colombia.
Oscar PeñuelaMedical Affairs, Bayer S.A., Bogotá, Colombia.
Maria Del Rosario ForeroMedical Affairs, Bayer S.A., Bogotá, Colombia.
Juan SatizabalIPSOS Napoleon Franco S.A., Bogotá, Colombia.
Ximena SalazarIPSOS Napoleon Franco S.A., Bogotá, Colombia.
Diana BenavidesIPSOS Napoleon Franco S.A., Bogotá, Colombia.
Raul GamarraIPSOS Napoleon Franco S.A., Bogotá, Colombia.
Marcela RiveraBayer Pharmaceuticals, Sant Joan Despi, Spain.
David VizcayaBayer Pharmaceuticals, Sant Joan Despi, Spain.ORCID 0000-0003-0248-7636
Juan-Sebastian FrancoMedical Affairs, Bayer S.A., Bogotá, Colombia.ORCID 0000-0001-7776-9270

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Collecting and interpreting self-reported outcomes among people with hemophilia A supports the understanding of the burden of the disease and its treatment to improve holistic care. However, in Colombia, this information is limited. Therefore, this study aimed to describe the knowledge, perception and burden of hemophilia A from the patients' perspective. A cross-sectional study was conducted in the context of a hemophilia educational bootcamp held from November 29th to December 1st, 2019, in Medellin, Colombia. The bootcamp was organized by a hemophilia patient association responsible for contacting and inviting patients with hemophilia A (PwHA). Information on patients' health beliefs, treatment experiences, and health-related quality of life (HRQoL) was obtained through focus groups, individual interviews and the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. A total of 25 moderate or severe PwHA were enrolled in this study and completed the PROBE questionnaire. Acute pain was the most frequently reported symptom, with 88% of the patients reporting the use of pain medication. Difficulty with activities of daily living was reported by 48%. Furthermore, 52% reported having more than 2 spontaneous bleeding events in the last year. Treatment was administered at home for 72% of patients, with regular prophylaxis as the most common treatment regimen. In terms of overall HRQoL, the median EQ-5D VAS score was 80 (IQR: 50-100). PwHA in Colombia still suffer from disease complications related to bleeding events, pain and disability that affect their HRQoL, which highlights the need to develop patient-centered initiatives to improve the wellness of this population.

Indexed as

Hemophilia AActivities of Daily LivingCross-Sectional StudiesHemorrhageHumansLatin AmericaPainPatient Reported Outcome MeasuresQuality of Life

Identifiers

PMID37410717
PMCPMC10325071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.